AIM: To evaluate the effectiveness and safety of Conbercept for diabetic retinopathy(DR)systematically, in order to provide evidence-based reference for clinical use.

METHODS:We performed a comprehensive search for the randomized controlled trials(RCTs)about Conbercept trail group vs control group in the treatment of DR published from PubMed, Cochrane Library, CNKI and Wanfang Database. Studies obtained from eligible database were filtered according to modified Jadad scale, and data were retrieved from those studies for further analysis. Then, we performed a Meta analysis using RevMan 5.3 statistical software.

RESULTS:A total of 22 RCTs were included, involving 1 878 patients. The results of Meta-analysis showed that visual acuity at 1 and 3mo, the central macular retinal thickness(CMT), operation time, the level of vascular endothelial growth factor(VEGF)and the implicit time of N1 wave were markedly decreased after treatment; the scores of self-care ability, social ability, activity ability, and psychological ability and response rates after treatment were significantly improved; and which were statistically different to control group. As for safety, the incidences of anterior chamber inflammation reaction, corneal edema, ocular hypertension, bleeding in operation, vitreous hemorrhage, iatrogenic visual hiatus and retinal detachment, complication incidence were more significantly decreased than control group. The same results were gained in subgroup.

CONCLUSION:The existing evidence supports that conbercept has good therapeutic efficacy and safety for DR.